全文获取类型
收费全文 | 5463篇 |
免费 | 242篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 71篇 |
妇产科学 | 28篇 |
基础医学 | 620篇 |
口腔科学 | 109篇 |
临床医学 | 292篇 |
内科学 | 1696篇 |
皮肤病学 | 32篇 |
神经病学 | 448篇 |
特种医学 | 231篇 |
外科学 | 1006篇 |
综合类 | 15篇 |
预防医学 | 95篇 |
眼科学 | 18篇 |
药学 | 252篇 |
中国医学 | 6篇 |
肿瘤学 | 780篇 |
出版年
2023年 | 47篇 |
2022年 | 95篇 |
2021年 | 180篇 |
2020年 | 84篇 |
2019年 | 111篇 |
2018年 | 143篇 |
2017年 | 105篇 |
2016年 | 157篇 |
2015年 | 162篇 |
2014年 | 189篇 |
2013年 | 231篇 |
2012年 | 366篇 |
2011年 | 398篇 |
2010年 | 223篇 |
2009年 | 174篇 |
2008年 | 324篇 |
2007年 | 321篇 |
2006年 | 342篇 |
2005年 | 348篇 |
2004年 | 357篇 |
2003年 | 344篇 |
2002年 | 310篇 |
2001年 | 58篇 |
2000年 | 47篇 |
1999年 | 67篇 |
1998年 | 76篇 |
1997年 | 69篇 |
1996年 | 63篇 |
1995年 | 66篇 |
1994年 | 31篇 |
1993年 | 46篇 |
1992年 | 31篇 |
1991年 | 21篇 |
1990年 | 15篇 |
1989年 | 29篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 11篇 |
1985年 | 8篇 |
1984年 | 11篇 |
1983年 | 12篇 |
1982年 | 6篇 |
1981年 | 11篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1972年 | 2篇 |
1963年 | 2篇 |
1962年 | 1篇 |
排序方式: 共有5731条查询结果,搜索用时 15 毫秒
991.
Kawashima R Abei M Fukuda K Nakamura K Murata T Wakayama M Seo E Hasegawa N Mizuguchi H Obata Y Hyodo I Hamada H Yokoyama KK 《International journal of cancer. Journal international du cancer》2011,129(5):1244-1253
A critical issue in adenovirus (Ad)-based cancer gene therapy is to improve the specificity of gene delivery to cancer cells for better efficacy and safety. We explored methods of retargeting Ad vectors for selective gene therapy of human biliary cancers using the Ad incorporating an IgG Fc-binding motif (Z33) from the Staphylococcus protein A (Ad-FZ33) combined with tumor-specific antibodies. Flow cytometry analysis revealed high-expression levels of epithelial cell adhesion molecule (EpCAM) and epidermal growth factor receptor (EGFR) on human biliary cancer cells. Ad-FZ33 expressing LacZ combined with antibodies against EpCAM or EGFR, followed by β-gal assay, demonstrated highly efficient gene transduction in these biliary cancer cells, compared to the treatment with control antibody or without antibody. Ad-FZ33 expressing uracil phosphoribosyl transferase (UPRT), an enzyme which greatly enhances the toxicity of 5-fluorouracil (FU), combined with antibodies against EpCAM or EGFR, remarkably enhanced the sensitivity of biliary cancer cells to 5-FU. By contrast, the treatment did not affect the 5-FU sensitivity of the cells not expressing EpCAM or EGFR including normal hepatocytes. Finally, treatments with the UPRT-expressing Ad-FZ33 with antibodies against EpCAM or EGFR, followed by 5-FU administration, significantly suppressed the growth of biliary cancer xenografts in nude mice. These results indicate that the gene therapy mediated by the Z33 fiber modified Ad with anti-EpCAM or anti-EGFR antibodies offers a potentially effective therapeutic modality against biliary cancers. 相似文献
992.
Yamauchi C Fujii S Kimura T Kuwata T Wada N Mukai H Matsumoto N Fukayama M Ochiai A 《International journal of cancer. Journal international du cancer》2011,128(9):2125-2137
Trastuzumab is a recombinant antibody drug that is widely used for the treatment of HER2-overexpressing breast carcinoma. Despite encouraging clinical results, many HER2-overexpressing carcinomas are primarily resistant to trastuzumab. We attempted to explain trastuzumab resistance and search for solutions. Since the killer cell lectin-like receptor G1 (KLRG1), an inhibitory receptor expressed on subsets of natural killer (NK) cells recognizes E-cadherin as ligands and may inhibit immune responses by regulating the effector function of NK cells, we used HER2-overexpressing carcinoma cells which were expressing E-cadherin to investigate the role of antibody-dependent cellular cytotoxicity (ADCC) through KLRG1 on NK cells in vitro and vivo. The results indicated that HER2-overexpressing carcinoma cells were killed by trastuzumab-mediated ADCC and the ADCC activity was reflected the degree of E-cadherin expression on carcinoma cells. We found that expression of E-cadherin was shown to be a predictor of response to trastuzumab-based treatment for HER2-overexpressing carcinomas, furthermore, trastuzumab-mediated ADCC was markedly enhanced by KLRG1-negative peripheral blood mononuclear cells (PBMCs(KLRG1(-))). 相似文献
993.
994.
Hiroyuki Yamaguchi Hiroshi Soda Yoichi Nakamura Mineyo Takasu Nanae Tomonaga Hirofumi Nakano Seiji Doi Katsumi Nakatomi Seiji Nagashima Hiroshi Takatani Minoru Fukuda Tomayoshi Hayashi Kazuhiro Tsukamoto Shigeru Kohno 《Cancer chemotherapy and pharmacology》2011,67(2):331-338
Purpose
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment.Methods
We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250?mg gefitinib daily. Eligibility criteria included performance status ??3, age ??80?years, and stage IIIB?CIV disease. In addition, EGFR mutations were analyzed in 24 patients.Results
Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS.Conclusions
The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib. 相似文献995.
Nakano H Saito N Parker L Tada Y Abe M Tsuganezawa K Yokoyama S Tanaka A Kojima H Okabe T Nagano T 《Journal of medicinal chemistry》2012,55(11):5151-5164
Serine/threonine kinase PIM1 is an emerging therapeutic target for hematopoietic and prostate cancer therapy. To develop a novel PIM1 inhibitor, we focused on 1, a metabolically labile, nonselective kinase inhibitor discovered in our previous screening study. We adopted a rational optimization strategy based mainly on structural information for the PIM1-1 complex to improve the potency and selectivity. This approach afforded the potent and metabolically stable PIM1-selective inhibitor 14, which shows only a marginal increase in molecular weight compared with 1 but has a significantly decreased cLogP. The validity of our design concept was confirmed by X-ray structure analysis. In a cellular study, 14 potently inhibited the growth of human leukemia cell line MV4-11 but had a negligible effect on the growth of WI-38 (surrogate for general toxicity). These results demonstrate the effectiveness of our design strategy for evolving the screening-hit compound 1 into a novel type of PIM1 inhibitor, 14. 相似文献
996.
Tamaki H Satoh H Hori S Sawada Y 《Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan》2012,132(4):525-529
Confusion of drug names is one of the most common causes of drug-related medical errors. A similarity measure of drug names, "vwhtfrag", was developed to discriminate whether drug name pairs are likely to cause confusion errors, and to provide information that would be helpful to avoid errors. The aim of the present study was to evaluate and improve vwhtfrag. Firstly, we evaluated the correlation of vwhtfrag with subjective similarity or error rate of drug name pairs in psychological experiments. Vwhtfrag showed a higher correlation to subjective similarity (college students: r=0.84) or error rate than did other conventional similarity measures (htco, cos1, edit). Moreover, name pairs that showed coincidences of the initial character strings had a higher subjective similarity than those which had coincidences of the end character strings and had the same vwhtfrag. Therefore, we developed a new similarity measure (vwhtfrag+), in which coincidence of initial character strings in name pairs is weighted by 1.53 times over coincidence of end character strings. Vwhtfrag+ showed a higher correlation to subjective similarity than did unmodified vwhtfrag. Further studies appear warranted to examine in detail whether vwhtfrag+ has superior ability to discriminate drug name pairs likely to cause confusion errors. 相似文献
997.
Sasaki T Isayama H Nakai Y Mizuno S Yamamoto K Yagioka H Yashima Y Kawakubo K Kogure H Togawa O Matsubara S Ito Y Sasahira N Hirano K Tsujino T Toda N Tada M Omata M Koike K 《Investigational new drugs》2012,30(2):708-713
Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy. However, there is no standard chemotherapy for patient with advanced BTC refractory to gemcitabine. We conducted a multicenter phase II study of S-1 monotherapy as second-line chemotherapy for patients with advanced BTC that were refractory to gemcitabine. S-1 was administered orally at a dose of 80 mg/m(2) for 28 days, followed by 14 days of rest. This regimen was repeated every 6 weeks. Tumor response was assessed every two cycles using the Response Evaluation Criteria in Solid Tumors version 1.0. Twenty-two patients were enrolled between March 2007 and January 2010, with 14 patients (64%) representing cases of recurrence after surgery. The overall response rate was 22.7%, and the overall disease control rate was 50.0%. The median overall survival time was 13.5 months (95% CI, 7.1-23.1 months) and the median time-to-progression was 5.4 months (95% CI, 2.6-17.2 months). Grade 3/4 toxicities included neutropenia (5%) and anemia (5%). The most common non-hematological toxicities were nausea (27%), anorexia (55%), and pigmentation (32%). In conclusion, S-1 monotherapy is feasible and moderately efficacious second-line chemotherapy for advanced BTC. 相似文献
998.
Nakabayashi K Tajima A Yamamoto K Takahashi A Hata K Takashima Y Koyanagi M Nakaoka H Akamizu T Ishikawa N Kubota S Maeda S Tsunoda T Kubo M Kamatani N Nakamura Y Sasazuki T Shirasawa S 《Journal of human genetics》2011,56(11):772-778
To identify genetic variants that confer the risk of Graves' disease (GD) in the Japanese population, we conducted a two-stage genome-wide association study (GWAS) using 1119 Japanese individuals with GD and 2718 unrelated controls, and a subsequent replication study using independent 432 GD cases and 1157 controls. We identified 34 single nucleotide polymorphisms (SNPs) to be significantly associated with GD in the GWAS phase. Twenty-two out of 34 SNPs remained positive in the replication study. All 22 SNPs were located within the major histocompatibility complex (MHC) locus on chromosome 6p21. No strong long-range linkage disequilibrium (LD) was observed among the 22 SNPs, indicating independent involvement of multiple loci within the MHC with the risk of GD. Multivariate stepwise logistic regression analysis selected rs3893464, rs4313034, rs3132613, rs4248154, rs2273017, rs9394159 and rs4713693, as markers for independent risk loci for GD. The analysis of LD between these seven SNPs and tagging SNPs for GD-associated human leukocyte antigen (HLA) alleles in the Japanese population (HLA-DPB1(*)0501 and HLA-A(*)0206) demonstrated that all of and five of seven SNPs were not in strong LD with HLA-DPB1(*)0501 and HLA-A(*)0206, respectively. Although causal variants remain to be identified, our results demonstrate the existence of multiple GD susceptibility loci within the MHC region. 相似文献
999.
Niihori T Aoki Y Okamoto N Kurosawa K Ohashi H Mizuno S Kawame H Inazawa J Ohura T Arai H Nabatame S Kikuchi K Kuroki Y Miura M Tanaka T Ohtake A Omori I Ihara K Mabe H Watanabe K Niijima S Okano E Numabe H Matsubara Y 《Journal of human genetics》2011,56(10):707-715
Costello syndrome (CS) is a congenital disease that is characterized by a distinctive facial appearance, failure to thrive, mental retardation and cardiomyopathy. In 2005, we discovered that heterozygous germline mutations in HRAS caused CS. Several studies have shown that CS-associated HRAS mutations are clustered in codons 12 and 13, and mutations in other codons have also been identified. However, a comprehensive comparison of the substitutions identified in patients with CS has not been conducted. In the current study, we identified four mutations (p.G12S, p.G12A, p.G12C and p.G12D) in 21 patients and analyzed the associated clinical manifestations of CS in these individuals. To examine functional differences among the identified mutations, we characterized a total of nine HRAS mutants, including seven distinct substitutions in codons 12 and 13, p.K117R and p.A146T. The p.A146T mutant demonstrated the weakest Raf-binding activity, and the p.K117R and p.A146T mutants had weaker effects on downstream c-Jun N-terminal kinase signaling than did codon 12 or 13 mutants. We demonstrated that these mutant HRAS proteins induced senescence when overexpressed in human fibroblasts. Oncogene-induced senescence is a cellular reaction that controls cell proliferation in response to oncogenic mutation and it has been considered one of the tumor suppression mechanisms in vivo. Our findings suggest that the HRAS mutations identified in CS are sufficient to cause oncogene-induced senescence and that cellular senescence might therefore contribute to the pathogenesis of CS. 相似文献
1000.
Acute effects of walking in forest environments on cardiovascular and metabolic parameters 总被引:3,自引:0,他引:3
Li Q Otsuka T Kobayashi M Wakayama Y Inagaki H Katsumata M Hirata Y Li Y Hirata K Shimizu T Suzuki H Kawada T Kagawa T 《European journal of applied physiology》2011,111(11):2845-2853
We previously found that forest environments reduced stress hormones such as adrenaline and noradrenaline and showed the relaxing effect both in male and female subjects. In the present study, we investigated the effects of walking under forest environments on cardiovascular and metabolic parameters. Sixteen healthy male subjects (mean age 57.4?±?11.6?years) were selected after obtaining informed consent. The subjects took day trips to a forest park in the suburbs of Tokyo and to an urban area of Tokyo as a control in September 2010. On both trips, they walked for 2?h in the morning and afternoon on a Sunday. Blood and urine were sampled on the morning before each trip and after each trip. Blood pressure was measured on the morning (0800) before each trip, at noon (1300), in the afternoon (1600) during each trip, and on the morning (0800) after each trip. The day trip to the forest park significantly reduced blood pressure and urinary noradrenaline and dopamine levels and significantly increased serum adiponectin and dehydroepiandrosterone sulfate (DHEA-S) levels. Walking exercise also reduced the levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and urinary dopamine. Taken together, habitual walking in forest environments may lower blood pressure by reducing sympathetic nerve activity and have beneficial effects on blood adiponectin and DHEA-S levels, and habitual walking exercise may have beneficial effects on blood NT-proBNP levels. 相似文献